Serum
alpha 1-acid glycoprotein (alpha 1AG) concentrations were determined in 55 dogs with previously untreated, histologically confirmed, high-grade
lymphoblastic lymphoma, and in 34 dogs with histologically confirmed nonhematopoietic
malignancies (13 dogs with
carcinomas and 21 dogs with
sarcomas). Serum concentrations were again determined in 32 dogs with
lymphoma that were
in complete remission 3 weeks after 1 dose of
doxorubicin (30 mg/m2 of body surface, i.v.) and in 22 dogs that were still
in complete remission 3 weeks after a fourth dose of
doxorubicin. For comparison, serum alpha 1AG concentrations were measured in 19 clinically normal (control) dogs of similar weight and age. Eight of the control dogs were given 1 dose of
doxorubicin (30 mg/m2, i.v.), and serum alpha 1AG concentrations were measured 3 weeks later. In control dogs, mean serum alpha 1AG concentration
after treatment with
doxorubicin was not significantly different from mean concentration before treatment. Mean alpha 1AG concentrations in untreated dogs with
lymphoma, in dogs with
sarcomas, and in dogs with
carcinomas were all significantly higher than mean concentration for untreated control dogs. In addition, the mean concentration for dogs with
osteosarcomas was significantly higher than mean concentration for untreated control dogs. There were no significant differences in mean serum alpha 1AG concentrations among dogs with different clinical stages of
lymphoma (stage IIIa, stage IVa, stage Va). However, mean serum alpha 1AG concentrations were significantly increased for dogs with stages IIIa, IVa, and Va
lymphoma, compared with mean concentration for untreated control dogs.(ABSTRACT TRUNCATED AT 250 WORDS)